GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » ROE % Adjusted to Book Value

CAMRF (Camurus AB) ROE % Adjusted to Book Value : 0.87% (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Camurus AB ROE % Adjusted to Book Value?

Camurus AB's ROE % for the quarter that ended in Jun. 2024 was 10.61%. Camurus AB's PB Ratio for the quarter that ended in Jun. 2024 was 12.23. Camurus AB's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 0.87%.


Camurus AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Camurus AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB ROE % Adjusted to Book Value Chart

Camurus AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.08 -3.44 -1.35 0.45 4.18

Camurus AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.34 2.63 -0.51 1.43 0.87

Competitive Comparison of Camurus AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Camurus AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Camurus AB's ROE % Adjusted to Book Value falls into.



Camurus AB ROE % Adjusted to Book Value Calculation

Camurus AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=34.85% / 8.33
=4.18%

Camurus AB's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.61% / 12.23
=0.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camurus AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Camurus AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB Business Description

Industry
Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.